The International CardiOncology Society An Update for 2014

The International CardiOncology SocietyAn Update for 2014

Daniel J Lenihan, MDProfessor, Division of Cardiovascular MedicineDirector, Clinical ResearchVanderbilt University

The International CardiOncology SocietyAn Update

• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?

ICOS is:

• A collection of interested providers focused on improving cardiac health in cancer patients

• A mix of academic, practice, governmental, regulatory, and industry professionals

• Committed to our patients wherever they are

The International CardiOncology SocietyAn Update

• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?

We do things in many ways:• Day to day improvement in our practices• Monthly webinars available to all• Periodic presentations at major meetings• Annual ICOS congresses• Development of current “Best Practice”• Data review for ongoing early phase and late phase

clinical trials• Ongoing participation in major professional society

efforts• Ongoing individual and multicenter research• Consistent involvement with regulatory agencies in many

countries

The International CardiOncology SocietyAn Update

• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?

ICOS goals• Research

– Engage large databases– Cardiac safety endpoint

adjudication– Hypothesis testing

research

• Advocacy• Patients/families• Providers

• Education– Provider case review– Patient directed – Professional meetings– Industry/regulatory webinars– Trainee organization

• Be a Resource• Up to Date information• Identify Goals for the future• Provide innovation• Be an example of

collaboration

0

50

100

150

200

250

300

350

400

Chart TitleNumber of PUBMED articles on Cardio-Oncology

1971 2014

www.oncoreview.pl

The International CardiOncology SocietyAn Update

• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?

PREDICT Study: A multicenter study in Patients undergoing

anthRacycline-based chemotherapy to assess the Effectiveness of using biomarkers to Detect and Identify Cardiotoxicity and describe Treatment

Daniel J Lenihan, MDProfessor, Division of Cardiovascular MedicineVanderbilt UniversityCCOP Annual Meeting 2010

TotalAccrual:597 patients

Slamon D et al; NEJM 2011:365:1273-83

In the case of HER2+ breast cancer, treatment clearly benefitted the disease but came at a cost

0%0%0%

1-2

7%

28%

64%

0

20

40

60

80

100

2-4 4-6 6-8 8-10 10-12 >12

0%

(n=75) (n=35) (n=20) (n=12) (n=8) (n=7) (n=44)

months

Res

pon

der

s (%

)

D Cardinale, et al. JACC 2010, jan 26.

The effect of time for initiation of HF therapy and the percent of patients who

improve

In regards to Ischemic insults, we have a paradigm

Kloner et al, Circ 2001; p2981

Statin therapy prior to and during chemotherapy was protective

JACC 2012, p 2384

Prevention of Cardiotoxicity is possible

Bosch, X et al, JACC 2013, p 2355

Are there things on the cancer therapy horizon that could be concerning for

cardiomyopathy?

There is a balance between protein synthesis and degradation

Monte S. Willis, M.D., Ph.D., and Cam Patterson, M.D., M.B.A. NEJM 2013;368:455-64.

Dick,LR and Flemming,PE Drug Discovery Today ;15 (5/6) March 2010

The International CardiOncology SocietyAn Update

• Exactly what does this society mean?• How do we do things?• What are our goals?• How do we achieve them?• Is there really a future for this?

Kouri M et al. Circulation 2012

A Paradigm for Cardiology Oncology Cooperation

ICOS=

A public, private, patient, provider, regulatory, governmental PARTNERSHIP

www.icosna.org